Skip to main content
. Author manuscript; available in PMC: 2018 Nov 1.
Published in final edited form as: Breast J. 2017 Aug 28;23(6):718–722. doi: 10.1111/tbj.12905

Table 2.

Survival, progression of disease, and lines of chemotherapy

EOLC4
N=62
Non-EOLC
N=212
EOLC4 vs Non-EOLC (p-value)
Median Survival months (range) 21 (2 – 104) 32 (2 – 167) 0.04
Age at diagnosis of primary cancer median (range) 47 (31–71) 52 (25–88) 0.003
Age at metastatic cancer diagnosis median (range) 50 (35–74) 56 (26–89) 0.001
Number of metastatic sites mean (SD) 3.5 (1.2) 2.8 (1.3) 0.0002
Total lines of chemotherapy mean (SD) 4.3 (2.4) 2.8 (2.3) <0.0001